Dynavax and Coalition for Epidemic Preparedness Innovations (CEPI) join hands to develop vaccines against Coronavirus (COVID-19)

India: Dynavax Technologies Corporation, a fully integrated biopharmaceutical company specialized in developing and commercializing novel vaccines, and Coalition for Epidemic Preparedness Innovations (CEPI), a foundation that provides financial support to research organizations and projects to develop vaccines against forthcoming diseases by collecting donations from private, public and other organizations, have joined hands to develop vaccines against the prevalent Coronavirus. Dynavax has announced to provide one of its own toll-like receptors 9 (TLR9) agonist adjuvant, CpG 1018 to initiate the development of vaccines against the highly fatal and communicable COVID-19.

Chief Executive Officer of Dynavax stated, “Dynavax’s mission is to develop and commercialize innovative vaccines to prevent disease and support patients.” He further added, “We are proud to support CEPI’s efforts to address this global public health emergency with our advanced adjuvant technology.”

Previously, Dynavax also developed the adjuvant CpG 1018 used in the vaccine HEPLISAV-B against the disease Hepatitis B. The vaccine was approved by the U.S. Food and Drug Administration (FDA). CpG 1018 provides a significant safety database and an advanced technology expediting the manufacture and development of COVID-19 vaccine on a large scale.

The previous initiative of CEPI to develop vaccines against COVID-19 led to the collaboration of Dynavax and the University of Queensland, Australia. Dynavax will now be working with CEPI to coordinate with the global entities researching and working on the development of vaccines against the epidemic. The soul motive of the collaboration is to provide a rapid immune response with the assistance of CpG 1018.

According to TechSci Research, this collaboration is an initiative towards the development of vaccines against COVID-19. The market of Dynavax is expected to reap high benefits from this collaboration, as the vaccines developed will be circulated globally and will profit a huge part of population. This initiative will hopefully reflect good results as it will help control the fatal epidemic, whose outbreak has slowed down the global economy and financial markets.

According to the published report by TechSci Research, “Global Coronavirus Diagnostics Market By Type of Test (Molecular v/s Serology), By User (Single v/s Multiple), By Full Test Time (Less Than 60 Minutes, 1 Hours to 12 Hours, 13 Hours-24Hours, More Than 1 Days), By End User (Hospitals, Public Health Labs, Private or Commercial Labs, Physician Labs, Others), By Region, Forecast & Opportunities, 2025”, global coronavirus diagnostics market is expected to grow at a formidable rate during the forecast period. The global coronavirus diagnostics market is driven by increasing prevalence of this disease across different parts of the globe. Additionally, lack of kits or tests available to diagnose the disease is further expected to propel the growth of market during the forecast years.

According to the recently published report by TechSci Research, “Global Chloroquine Market By Type (Injectables, Capsules, Tablets), By Route of Administration (Oral v/s Intravenous), By Dosage (5mg, 500mg, 1000mg), By Application (Arthrophlogosis, Malaria, COVID-19, Others), By Region, Forecast & Opportunities, 2030”, global chloroquine market is expected to grow at a formidable rate during the forecast period. Chloroquine is commonly available in the market under the generic brand name Aralen. Several other formulations of chloroquine are also available that are sold under different brand names. Chemically, chloroquine is 7-chloro-4-[[4-(diethylamino)-1-methylbutyl] amino] quinoline phosphate and is used for treatment of various diseases such as rheumatoid arthritis, malaria, among others. The global chloroquine market is driven by the increasing use of the drug for treating various diseases. Recently, it has been identified though not approved by the FDA that the drug can be helpful in the treatment of novel coronavirus disease. The clinical trials are going on, but nothing has proved to be fruitful yet.